Chimeric antigen receptor (CAR) T cell immunotherapy aims to redirect a patient’s T cells to recognize and destroy malignant cells. These cells are genetically altered to express CARs that combine an ...
NATICK, Mass.--(BUSINESS WIRE)--AffyImmune, a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, presented preclinical data on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results